Form 4: REGENXBIO Director Alexandra Glucksmann Reports Significant Equity Awards

REGENXBIO Inc. Director Alexandra Glucksmann has reported the acquisition of 7,768 restricted stock units and 39,815 stock options as part of her compensation, increasing her beneficial ownership in the company.

Summary

• Alexandra Glucksmann, a Director at REGENXBIO Inc. (RGNX), acquired 7,768 shares of common stock through a Restricted Stock Unit (RSU) award on May 30, 2025.
• These RSU shares were granted at a price of $0.00 and will fully vest on May 1, 2026, contingent on her continuous service to the Issuer.
• Additionally, Ms. Glucksmann acquired 39,815 stock options on May 30, 2025, with an exercise price of $8.85 per share.
• These stock options were granted at a price of $0.00 and will vest in 12 equal monthly installments following May 31, 2024, also subject to her continuous service.
• The stock options have an expiration date of May 30, 2035.
• Following these transactions, Ms. Glucksmann beneficially owns 19,054 shares of common stock and 39,815 stock options directly.

Sentiment

Score: 7

Explanation: The acquisition of equity awards by a director, particularly stock options with an exercise price, generally indicates alignment of interests and potential confidence in future stock performance, which is a positive signal for investors. The awards are compensation, so not a direct 'buy' by the director, but still positive.

Positives

• Director Alexandra Glucksmann received significant equity awards (7,768 RSUs and 39,815 stock options), aligning her interests with shareholders.
• The acquisition of stock options with an exercise price of $8.85 indicates a potential belief in future stock price appreciation above this level.

Risks

• The vesting of both RSUs and stock options is subject to the continuous service of the recipient, meaning the awards could be forfeited if service is terminated.

Related Party Transactions

• The RSU and stock option awards are compensation to a director, which is a common form of related party transaction in corporate governance, designed to align director and shareholder interests.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders through equity ownership, potentially signaling confidence in the company's future.

Next Steps

• Continued service of Alexandra Glucksmann to REGENXBIO Inc. for vesting of equity awards.
• Vesting of 7,768 RSU shares on May 1, 2026.
• Monthly vesting of 39,815 stock options over 12 installments following May 31, 2024.

Key Dates

Recommendation

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, Beneficial Ownership, Biotechnology, Gene Therapy